Cornillon Jérôme, Sicre de Fontbrune Flore, Chantepie Sylvain, Coiteux Valérie, Gauthier Jordan, Masouridi-Levrat Stavroula, Pochon Cécile, Terriou Louis, Yakoub-Agha Ibrahim, Dalle Jean-Hugues
Institut de cancérologie Lucien-Neuwirth, service d'hématologie clinique, 42000 St-Etienne, France.
AP-HP, hôpital St-Louis, service d'hématologie - greffes de moelle, 75010 Paris, France.
Bull Cancer. 2016 Nov;103(11S):S248-S254. doi: 10.1016/j.bulcan.2016.09.004. Epub 2016 Oct 31.
Success of allogeneic hematopoietic stem cells transplantation requires both the underlying disease eradication and satisfying reconstitution of hematopoiesis from donor cells. However, reconstitution delays, secondary development or persistence of cytopenia are regularly observed and are potential causes of failure after allogeneic transplantation. These graft dysfunctions should be distinguished from non-engraftment/engraftment failure. Although these situations are relatively common, there is no consensus in the literature for their management. During the workshop of the SFGM-TC, the working group proposed recommendations from an analysis of the literature.
异基因造血干细胞移植的成功需要根除基础疾病并使供体细胞的造血功能得到满意的重建。然而，经常观察到造血重建延迟、血细胞减少的继发发展或持续存在，这些都是异基因移植后潜在的失败原因。这些移植物功能障碍应与未植入/植入失败相区分。尽管这些情况相对常见，但文献中对于它们的处理尚无共识。在SFGM-TC研讨会期间，工作组通过对文献的分析提出了建议。
